Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 621
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TF04310E854EN
Leaflet:

Download PDF Leaflet

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2016, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 29, 21, 3, 106, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 29 and 6 molecules, respectively.Type 1 Diabetes (Juvenile Diabetes).

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Type 1 Diabetes (Juvenile Diabetes) Overview
Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Products Glance
Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
Drug Profiles
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
Appendix 595

LIST OF TABLES

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AbGenomics International, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH and Co KG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ConjuChem, LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by enGene, Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Private Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Strongbridge Biopharma plc , H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..1), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..2), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..3), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..4), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..5), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..6), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..7), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..8), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..9), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..10), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..11), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..12), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..1), H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..2), H2 2016 606

LIST OF FIGURES

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Type 2 Diabetes - Pipeline Review, H2 2016 US$ 2,500.00 Nov, 2016 · 1298 pages

Ask Your Question

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: